Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding of differences between methods can lead to an improved ER, PgR, and HER-2 assessment. The purpose of this preplanned translational research is to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Viale, Giuseppe, Slaets, Leen, de Snoo, Femke A., Bogaerts, Jan, Russo, Leila, van’t Veer, Laura, Rutgers, Emiel J. T., Piccart-Gebhart, Martine J., Stork-Sloots, Lisette, Dell’Orto, Patrizia, Glas, Annuska M., Cardoso, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764628/
https://www.ncbi.nlm.nih.gov/pubmed/26820652
http://dx.doi.org/10.1007/s10549-016-3690-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764628/
https://www.ncbi.nlm.nih.gov/pubmed/26820652
http://dx.doi.org/10.1007/s10549-016-3690-6

Ejemplares similares